What are the major opportunities in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market? What are the strategies for the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market?

For detailed insights on the major opportunities and strategies in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market, Read More

How does the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market relate to the overall economy and other similar markets?

For detailed insights on the key dynamics influencing the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market growth and SWOT analysis of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment industry, Read More

Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report 2025

Item added to cart!

Published : December 2025

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00 $3367.00

Purchase This Report Download Sample PDF

Purchase This Report

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Global Market Report 2025

Name: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Type (Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types), By Indication (Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis), By End-Users (Hospitals, Homecare, Specialty Clinics, Other End Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

• Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market size has reached to $10.36 billion in 2024

• Expected to grow to $35.5 billion in 2029 at a compound annual growth rate (CAGR) of 27.8%

• Growth Driver: Impact Of Chronic Disease Prevalence On The Growth Of The Market

• Market Trend: Innovative Oral Treatments Drive Growth In The Market

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?

Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment refers to medical therapies and interventions aimed at managing ATTR-CM, a progressive and life-threatening disease caused by the buildup of misfolded transthyretin (TTR) proteins in the heart, leading to restrictive cardiomyopathy and heart failure.

The main types of transthyretin amyloid cardiomyopathy (ATTR-CM) treatment are transthyretin stabilizers, nonsteroidal anti-inflammatory drugs (NSAIDs), RNAi therapy, and other types. Transthyretin stabilizers are drugs that prevent transthyretin protein misfolding, reducing amyloid deposits and slowing disease progression in ATTR-CM. The various clinical indications include wild-type ATTR amyloidosis and hereditary ATTR amyloidosis. The treatment is used by various end-users, including hospitals, home care, specialty clinics, and others.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size and growth rate 2025 to 2029: Graph

What Is The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size 2025 And Growth Rate?

The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market size has grown exponentially in recent years. It will grow from $10.36 billion in 2024 to $13.29 billion in 2025 at a compound annual growth rate (CAGR) of 28.2%. The growth in the historic period can be attributed to rising prevalence of transthyretin amyloid cardiomyopathy, increasing prevalence of transthyretin amyloidosis among geriatric patients, increasing awareness among healthcare professionals and patients, growth in awareness and improvement of healthcare services.

What Is The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Growth Forecast?

The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market size is expected to see exponential growth in the next few years. It will grow to $35.5 billion in 2029 at a compound annual growth rate (CAGR) of 27.8%. The growth in the forecast period can be attributed to increasing prevalence of transthyretin amyloidosis, rise in diagnosis of neuropathic disorders, rising demographic of aging population, increase in demand for specific drugs for treating symptoms of the rare disorder, increasing demand for healthcare. Major trends in the forecast period include new diagnostic technologies, development of innovative techniques for the therapy management, innovative and targeted treatments for transthyretin amyloidosis, advancements in diagnostics techniques, cardiac MRI techniques.

The forecast of 27.8% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. cardiology centers by driving up the cost of tafamidis therapies and cardiac MRI contrast agents sourced from Switzerland and Belgium, exacerbating treatment expenses for this progressive fatal condition. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Segmented?

1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types

2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Transthyretin Stabilizers: Tafamidis, Diflunisal

2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): aspirin, Ibuprofen, Other NSAIDs

3) By RNAi Therapy: Patisiran, Vutrisiran

4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies

What Is Driving The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market? Impact Of Chronic Disease Prevalence On The Growth Of The Market

The rising prevalence of chronic diseases is expected to propel the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market going forward. Chronic diseases are long-lasting conditions that progress slowly and persist for a year or more, often requiring continuous medical care. The rising prevalence of chronic diseases is attributed to factors such as aging populations, sedentary lifestyles, unhealthy diets, increasing obesity rates, and exposure to environmental pollutants. Transthyretin amyloid cardiomyopathy treatment helps by stabilizing transthyretin, reducing amyloid buildup, improving heart function, and alleviating symptoms to better manage related chronic conditions. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year. Globally, there were 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. Therefore, the rising prevalence of chronic diseases is driving the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment industry.

Who Are The Major Players In The Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?

Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG

What Are The Key Trends Of The Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market? Innovative Oral Treatments Drive Growth In The Market

Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are focusing on developing innovative treatments for ATTR-CM, such as oral prescription medication to target and stabilize transthyretin (TTR) proteins or reduce amyloid fibril buildup in the heart. Oral prescription medication refers to drugs prescribed by a healthcare provider that are taken by mouth, typically in the form of tablets, capsules, or liquid solutions. For instance, in November 2024, BridgeBio Pharma Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration for Attruby (acoramidis) for the treatment of adults with transthyretin amyloid cardiomyopathy (ATTR-CM). This stabilizes the TTR protein, reducing heart-related deaths and hospitalizations. Clinical trials have shown that it is well-tolerated and provides rapid benefits by targeting the root cause of the disease.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market? Astrazeneca Partners With Neurimmune To Develop NI006 For Treating ATTR-CM

In January 2022, AstraZeneca Plc, a UK-based pharmaceutical industry company that develops and sells prescription medicines, partnered with Neurimmune AG. With this partnership, both the companies aim to develop NI006 for treating ATTR-CM by targeting amyloid deposits in the heart. Neurimmune AG is a Switzerland-based biopharmaceutical company that offers transthyretin amyloid cardiomyopathy (ATTR-CM) treatment.

What Is The Regional Outlook For The Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?

North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?

The transthyretin amyloid cardiomyopathy (ATTR-CM) market consists of revenues earned by entities by providing services such as diagnosis and screening services, pharmaceutical and drug therapies, patient monitoring and disease management, specialized treatment centers and hospital services. The market value includes the value of related goods sold by the service provider or included within the service offering. The transthyretin amyloid cardiomyopathy (ATTR-CM) market also includes sales of tafamidis, patisiran, vutrisiran, and acoramidis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Industry?

The transthyretin amyloid cardiomyopathy (attr-cm) treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the transthyretin amyloid cardiomyopathy (attr-cm) treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Transthyretin Amyloid Cardiomyopathy ATTRCM Treatment Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$13.29 billion
Revenue Forecast In 2034	$35.5 billion
Growth Rate	CAGR of 27.8% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market covered in this report is segmented – 1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types 2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis 3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users Subsegments: 1) By Transthyretin Stabilizers: Tafamidis, Diflunisal 2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen, Other NSAIDs 3) By RNAi Therapy: Patisiran, Vutrisiran 4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Characteristics

3. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Trends And Strategies

4. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Growth Analysis And Strategic Analysis Framework

5.1. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Growth Rate Analysis

5.4. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Total Addressable Market (TAM)

6. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Segmentation

6.1. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Transthyretin Stabilizers

Nonsteroidal Anti-inflammatory Drugs (NSAID)

RNAi Therapy

Other Types

6.2. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Wild type ATTR Amyloidosis

Hereditary ATTR amyloidosis

6.3. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Homecare

Specialty Clinics

Other End Users

6.4. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Transthyretin Stabilizers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Tafamidis

Diflunisal

6.5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Aspirin

Ibuprofen

Other NSAIDs

6.6. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of RNAi Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Patisiran

Vutrisiran

6.7. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Gene Silencing Therapies

Immunotherapy Approaches

Emerging Small Molecule Therapies

7. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Regional And Country Analysis

7.1. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

8.1. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

9.1. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

9.2. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

10.1. India Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

11.1. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

11.2. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

12.1. Australia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

13.1. Indonesia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

14.1. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

14.2. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

15.1. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

15.2. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

16.1. UK Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

17.1. Germany Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

18.1. France Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

19.1. Italy Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

20.1. Spain Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

21.1. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

21.2. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

22.1. Russia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

23.1. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

23.2. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

24.1. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

24.2. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

25.1. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

25.2. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

26.1. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

26.2. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

27.1. Brazil Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

28.1. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

28.2. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

29.1. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

29.2. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Competitive Landscape And Company Profiles

30.1. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Competitive Landscape

30.2. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Bayer AG. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

30.2.4. GlaxoSmithKline Plc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Other Major And Innovative Companies

31.1. Novo Nordisk A/S

31.2. Regeneron Pharmaceuticals Inc.

31.3. MedStar Health Inc

31.4. Alnylam Pharmaceuticals Inc

31.5. Ionis Pharmaceuticals Inc.

31.6. Akcea Therapeutics Inc

31.7. BridgeBio Pharma Inc.

31.8. Prothena Corporation plc

31.9. Intellia Therapeutics Inc.

31.10. Alexion Pharmaceuticals Inc.

31.11. Neurimmune Holding AG

31.12. SOM Biotech S.L

31.13. Corino Therapeutics Inc

31.14. Eidos Therapeutics Inc

31.15. CRISPR Therapeutics AG

32. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

34. Recent Developments In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

35. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market High Potential Countries, Segments and Strategies

35.1 Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market In 2029 - Countries Offering Most New Opportunities

35.2 Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market In 2029 - Segments Offering Most New Opportunities

35.3 Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Transthyretin Stabilizers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of RNAi Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Pfizer Inc. Financial Performance

Table 79: Bayer AG. Financial Performance

Table 80: AstraZeneca Plc Financial Performance

Table 81: GlaxoSmithKline Plc. Financial Performance

Table 82: Takeda Pharmaceutical Company Limited Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Transthyretin Stabilizers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of RNAi Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Pfizer Inc. Financial Performance

Figure 79: Bayer AG. Financial Performance

Figure 80: AstraZeneca Plc Financial Performance

Figure 81: GlaxoSmithKline Plc. Financial Performance

Figure 82: Takeda Pharmaceutical Company Limited Financial Performance

From Insight to Impact: Strategic Growth Mapping in the HER2-Positive Breast Cancer Market

Hospital And Nursing Home Probiotics Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

Next-Gen Implantable Cardioverter Defibrillators (ICDs) : Market Forecast, Transformation, and Long-Term Trajectories

Indwelling Catheters Growth Trajectory: Key Forecasts and Strategic Insights

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

A forward-looking 2025 report detailing projections, service trends and operational models in the medical accompaniment service market.

Hypertrophic Cardiomyopathy Treatment Global Market Report 2025 – By Disease Type (Obstructive Hypertrophic Cardiomyopathy Treatment, Non-Obstructive Hypertrophic Cardiomyopathy Treatment), By Diagnosis (Chest X-Ray, Ech...

Hypertrophic Cardiomyopathy (HCM) Therapeutics Global Market Report 2025 – By Drug Type (Antiarrhythmic Agents, Anticoagulants, Beta Adrenergic Blocking Agents, Calcium Channel Blockers, Other Drug Types), By Device Type...

Cardiometabolic Diseases Global Market Report 2025 – By Type (Chronic/Congestive Heart Failure, Hypertension, Type 2 Diabetes, Obesity), By Treatment (ACE inhibitors, Diuretics, Glucophage, Liposuction, Other Treatments)...

Ventricular Fibrillation Global Market Report 2025 – By Treatment (Cardiopulmonary Resuscitation (CPR), Defibrillation, Medication, Catheter Ablation, Left Cardiac Sympathetic Denervation), By Diagnostic Techniques (Elec...

Implantable Heart Pacemaker Global Market Report 2025 – By Product Type( Single Chamber, Dual Chamber, Biventricular), By Application( Heart Block, Sick Sinus Syndrome, Diagnosing Heart Diseases, Other Applications), By ...

Heart Blocks Treatment Devices Global Market Report 2025 – By Type (First-Degree Heart Block, Second-Degree Heart Block, Third-Degree Heart Block), By Product (Transcutaneous Pacing (TCP), Pacemaker, Mediation, Follow-Up...

Atrophic Glossitis Treatment Global Market Report 2025 – By Treatment Type (Medications, Topical Treatments, Nutritional Supplements, Oral Care Products), By Symptoms (Inflammation, Discoloration, Itching, Burning Tongue...

Frequently Asked Questions

What is the definition of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market?

How will the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market drivers and restraints affect the market dynamics? What forces will shape the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment industry going forward?

The market major growth driver - Impact Of Chronic Disease Prevalence On The Growth Of The Market. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market?

The transthyretin amyloid cardiomyopathy (attr-cm) treatment market size has grown exponentially in recent years. It will grow from $10.36 billion in 2024 to $13.29 billion in 2025 at a compound annual growth rate (CAGR) of 28.2%. The growth in the historic period can be attributed to rising prevalence of transthyretin amyloid cardiomyopathy, increasing prevalence of transthyretin amyloidosis among geriatric patients, increasing awareness among healthcare professionals and patients, growth in awareness and improvement of healthcare services. The transthyretin amyloid cardiomyopathy (attr-cm) treatment market size is expected to see exponential growth in the next few years. It will grow to " $35.5 billion in 2029 at a compound annual growth rate (CAGR) of 27.8%. The growth in the forecast period can be attributed to increasing prevalence of transthyretin amyloidosis, rise in diagnosis of neuropathic disorders, rising demographic of aging population, increase in demand for specific drugs for treating symptoms of the rare disorder, increasing demand for healthcare. Major trends in the forecast period include new diagnostic technologies, development of innovative techniques for the therapy management, innovative and targeted treatments for transthyretin amyloidosis, advancements in diagnostics techniques, cardiac MRI techniques. For further insights on this market, request a sample here

How is the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market segmented?

The transthyretin amyloid cardiomyopathy (attr-cm) treatmentmarket covered in this report is segmented –
1) By Type: Transthyretin Stabilizers; Nonsteroidal Anti-inflammatory Drugs (NSAID); RNAi Therapy; Other Types
2) By Indication: Wild type ATTR Amyloidosis; Hereditary ATTR amyloidosis
3) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End Users Subsegments:
1) By Transthyretin Stabilizers: Tafamidis; Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin; Ibuprofen; Other NSAIDs
3) By RNAi Therapy: Patisiran; Vutrisiran
4) By Other Types: Gene Silencing Therapies; Immunotherapy Approaches; Emerging Small Molecule Therapies For further insights on this market, request a sample here

Which region has the largest share of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market? What are the other regions covered in the report?

North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market?

What are the key trends in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market?

Major trends in this market include Innovative Oral Treatments Drive Growth In The Market. For further insights on this market, request a sample here.